Welcome to the e-CCO Library!

P573 Frequency and effectiveness of empirical anti-TNF dose intensification in inflammatory bowel disease: an on-going systematic review with meta-analysis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

L. Guberna Blanco, O.P. Nyssen, M. Chaparro, J.P. Gisbert

Created: Thursday, 30 January 2020, 10:12 AM
P573: Change in fatigue in patients with Ulcerative Colitis or Crohn's disease initiating vedolizumab or other biologic therapy: Data from Belgian registry patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Louis, E.(1)*;Bossuyt, P.(2);Colard, A.(3);Caenepeel, P.(4);Baert, F.(5);Hantson, A.(6);Van Gassen, G.(6);Zhou, J.(7);Vermeire, S.(8);
Created: Friday, 14 July 2023, 11:05 AM
P573: Comparative effectiveness of second-line biological therapies for Ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment
Year: 2021
Source: ECCO'21 Virtual
Authors: Hyun, H.K.(1);Yu, J.(1);Kang, E.A.(1);Park, J.(1);Park, S.J.(1);Park, J.J.(1);Kim, T.I.(1);Kim, W.H.(1);Cheon, J.H.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P573: Impact of the duration of combination therapy on clinical and pharmacological efficacy of infliximab in inflammatory bowel diseases
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Vernet C., Roblin X., Williet N.

Created: Wednesday, 20 February 2019, 10:36 AM
P573: Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive ulcerative colitis patients: Results from the EVOLVE study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Yarur*1, G. Mantzaris2, M. Silverberg3, M. Walshe3, P. Zezos3, D. Stein4, M. Bassel5, T. Lissoos6, C. Lopez6, A. Natsios7, G. Radulescu8, H. Patel9, D. Demuth10, B. Bressler11

Created: Friday, 22 February 2019, 9:41 AM
P573: Safety and immune modulatory properties of etrasimod (APD334), a next-generation oral, selective sphingosine 1-phosphate receptor (S1PR) modulator, in healthy volunteers
Year: 2018
Source: ECCO '18 Vienna
Authors:

L. Peyrin-Biroulet1, J. Adams2, S. Turner2, L. Trokan2, J. Panes3*

Created: Thursday, 21 February 2019, 9:14 AM
P573: The safety profile of upadacitinib maintenance therapy in ulcerative colitis in the Phase 3 U-ACHIEVE study is consistent with that in approved indications
Year: 2022
Source: ECCO'22
Authors: Colombel, J.F.(1);Panaccione, R.(2);Nakase, H.(3);Burmester, G.(4);Cohen, S.B.(5);Mease, P.(6);Guttman-Yassky, E.(1);Liu, J.(7);Zhou, W.(7);Ilo, D.(7);Higgins, P.(8);
Created: Friday, 11 February 2022, 3:56 PM
P574 Incidence and indicators of suboptimal response to tumour necrosis factor antagonist therapy in Chinese patients with inflammatory bowel disease: Results from the EXPLORE study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. Li1, Z. Li2, P. Hu3, Z. Wen4, Q. Cao5, X. Zou6, Y. Chen7, Y. Wang8, J. Zhong9, X. Shen10, D. Demuth11, O. Fedeeva11, L. Xie12, J. Chen12, J. Qian1

Created: Thursday, 30 January 2020, 10:12 AM
P574: Characterization of plasma inflammatory protein abundance in patients with ulcerative colitis treated with etrasimod: an exploratory analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Siegmund, B.(1)*;Ryan, R.(2);Abreu, M.T.(3);Vermeire, S.(4);Dotan, I.(5,6);Goetsch, M.(7);Crosby, C.(8);Woolcott, J.(9);Komori, H.K.(10);Danese, S.(11);
Created: Friday, 14 July 2023, 11:05 AM
P574: Exploring treatment of Crohn’s disease and ulcerative colitis in the Middle East and Northern Africa: An analysis of the HARIR observational cohort study
Year: 2021
Source: ECCO'21 Virtual
Authors: Hamed, W.(1);Salem, O.E.(2);Alharbi, O.(3);,4;Sharaf, M.(5);Taylor, C.(6);Sherief, A.(7);Besar, A.(6);
Created: Wednesday, 2 June 2021, 4:12 PM
P574: IBD patients should be stratified to guide out-of-hospital monitoring: ICHOM-derived outcomes from a dedicated IBD telephone clinic
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. K. Fofaria*1, S. Azana1, G. Grande1, P. Naeck-Boolauky1, T. Tyrrell1, N. Arebi1

Created: Friday, 22 February 2019, 9:41 AM
P574: Limitations and difficulties in using anti-TNF-alpha agents in inflammatory bowel disease. A survey of the Italian Group for Inflammatory Bowel Disease (IG-IBD)
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Saibeni S.*1, Bezzio C.1, Armuzzi A.2, Bossa F.3, Calabrese E.4, Caprioli F.5, Daperno M.6, Mocciaro F.7, Orlando A.8, Papi C.9, Rispo A.10, Rizzello F.11 IG-IBD

Created: Wednesday, 20 February 2019, 10:36 AM
P574: Population pharmacokinetic and exposure-response analyses for efficacy and safety of risankizumab in subjects with active Crohn‘s disease
Year: 2022
Source: ECCO'22
Authors: Suleiman, A.(1);Goebel, A.(1);Bhatnagar, S.(2);D'Cunha, R.(2);Liu, W.(2);Pang, Y.(2);
Created: Friday, 11 February 2022, 3:56 PM
P574: The effects of vagus nerve stimulation in biologic-refractory Crohn’s disease: A prospective clinical trial
Year: 2018
Source: ECCO '18 Vienna
Authors:

G. D'Haens1*, Z. Cabrijan2, M. Eberhardson3, R. van den Bergh1, M. Löwenberg1, G. Fiorino4, S. Danese4, Y. Levine5, D. Chernoff5

Created: Thursday, 21 February 2019, 9:14 AM
P575 Real-world effectiveness and safety of ustekinumab for the treatment of refractory Crohn’s disease: The Scottish ustekinumab cohort
Year: 2020
Source:

ECCO'20 Vienna

Authors:

N. PLEVRIS1, A. Robertson2, J. Fulforth1, R. Hall3, I. Campbell4, C. Kane5, J. Veryan6, W. Lam6, J. Saunders2, P. Jenkinson1, C. Chuah7, C. Kelly8, D. Watts8, D. Gaya6, J. Macdonald9, H. Jafferbhoy7, J.P. Seenan9, C. Mowat3, D. Sutherland2, G. Naismith10, G. Bain5, I. Arnott1, G. Jones1, C. Lees1

Created: Thursday, 30 January 2020, 10:12 AM
P575: AZA-related toxicity isn't aggravated by concomitant drugs in IBD patients
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Ladic A., Bozina N., Cukovic-Cavka S., Krznaric Z.

Created: Wednesday, 20 February 2019, 10:36 AM
P575: Effect of etrasimod on immune cell subsets in colonic tissue of patients with ulcerative colitis: immunophenotyping analysis of colon biopsy samples from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Siegmund, B.(1)*;Komori, H.K.(2);Abreu, M.T.(3);Vermeire, S.(4);Dotan, I.(5,6);Goetsch, M.(7);Crosby, C.(8);Ryan, R.(9);Woolcott, J.(10);Danese, S.(11);
Created: Friday, 14 July 2023, 11:05 AM
P575: Nutrition and Inflammatory Bowel Disease – a nationwide survey of patients, gastroenterologists and dietitians
Year: 2021
Source: ECCO'21 Virtual
Authors: McCarthy, N.(1);Schultz, M.(2);Wall, C.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P575: Safety and efficacy of autologous haematopoietic stem cell transplantation for refractory Crohn’s disease after cyclophosphamide-free mobilisation: Preliminary Results
Year: 2022
Source: ECCO'22
Authors: Giordano, A.(1);Rovira, M.(2);Barastegui, R.(1);Marín, P.(2);Martínez, N.(2);Fernández-Aviles, F.(2);Suárez-Lledó, M.(2);Doménech, A.(2);Ordás, I.(1);Fernández-Clotet, A.(1);Caballol, B.(1);Gallego, M.(1);Vara, A.(1);Masamunt, M.C.(1);Giner, A.(1);Corraliza, A.M.(3);Panés, J.(1);Salas, A.(3);Ricart, E.(1);
Created: Friday, 11 February 2022, 3:56 PM
P575: Simple novel tacrolimus enemas are very effective in severe refractory proctitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. R. Fehily*1, F. C. Martin1, M. A. Kamm1,2

Created: Friday, 22 February 2019, 9:41 AM